chlorotrianisene

Generic Name: chlorotrianisene (klor oh trye AN i seen) Brand Names: Tace

What is chlorotrianisene?

Chlorotrianisene is a form of estrogen. Estrogen is a female sex hormone necessary for many processes in the body.

Chlorotrianisene is used to treat symptoms of menopause, deficiencies in ovary function (including underdevelopment of female sexual characteristics and some types of infertility), and prostate cancer.

Chlorotrianisene may also be used for purposes other than those listed in this medication guide.

What is the most important information I should know about chlorotrianisene?

Have yearly physical exams and examine your breasts for lumps on a monthly basis while taking chlorotrianisene.

Take chlorotrianisene with food or milk to lessen stomach upset. Do not take chlorotrianisene if you are pregnant. Who should not take chlorotrianisene? Do not take chlorotrianisene if you

have breast cancer. Tell your doctor if you have (or have ever had) breast cancer.

have vaginal bleeding that has not been diagnosed. It will be necessary to determine if any abnormal bleeding has a hormonal cause.

have a bleeding or blood-clotting disorder. Chlorotrianisene may increase the risk that a blood clot will form.

Before taking this medication, tell your doctor if you

have any type of liver or gallbladder disease,

are diabetic,

suffer from migraines,

have epilepsy or seizures,

have heart disease, or

have kidney disease.

You may need a lower dose or special monitoring during treatment if you have any of the conditions listed above.

Chlorotrianisene is in the FDA pregnancy category X. This means that chlortrianisene will cause birth defects in an unborn baby. Do not take this medication if you are pregnant or are planning a pregnancy. Chlorotrianisene may decrease milk flow and have other effects on milk composition. Do not use this medication without first talking to your doctor if you are breast-feeding a baby. How should I take chlorotrianisene?

Take this medication exactly as directed by your doctor. If you do not understand these directions, ask your pharmacist, nurse, or doctor to explain them to you.

Take each dose with a full glass of water. Take chlorotrianisene with food or milk to lessen stomach upset.

Try to take each dose at the same time each day, preferably in the morning. You may be taking it every day, or you may be taking it every day for 3 weeks with 1 week off each month to mimic your body's natural cycle. Follow the directions on your prescription label.

If you are taking chlorotrianisene to treat cancer, you may be taking it several times a day in very large doses.

Store chlorotrianisene at room temperature away from moisture and heat. What happens if I miss a dose?

Take the missed dose as soon as you remember. Do not take a double dose of this medication unless otherwise directed by your doctor.

What happens if I overdose? An overdose of this medication is unlikely to threaten life. Consult an emergency room or poison control center for advice.

Symptoms of an estrogen overdose include nausea and vomiting.

What should I avoid while taking chlorotrianisene? Avoid prolonged exposure to sunlight. Chlorotrianisene may increase the sensitivity of your skin to sunlight. Use a sunscreen and wear protective clothing when exposure to the sun is unavoidable. Chlorotrianisene side effects If you experience any of the following serious side effects, stop taking chlorotrianisene and seek emergency medical attention:

an allergic reaction (difficulty breathing; closing of your throat; swelling of your lips, tongue, or face; or hives);

a blood clot (pain, redness, and swelling in an arm or leg, shortness of breath, chest pain, headache, blurred vision, or confusion);

a lump in a breast; or

liver damage (yellowing of the skin or eyes, nausea, abdominal pain or discomfort, unusual bleeding or bruising, severe fatigue).

Other, less serious side effects may be more likely to occur. Continue to take chlorotrianisene and talk to your doctor if you experience

decreased appetite, nausea, or vomiting;

swollen breasts;

acn? or skin color changes;

decreased sex drive;

migraine headaches or dizziness;

water retention (swollen hands, feet, or ankles);

depression; or

changes in your menstrual cycle or breakthrough bleeding.

Side effects other than those listed here may also occur. Talk to your doctor about any side effect that seems unusual or that is especially bothersome.

What other drugs will affect chlorotrianisene?

Chlorotrianisene may decrease the effects of the following drugs:

anticoagulants (blood thinners) such as warfarin (Coumadin). This could lead to blood clots. Your doctor will want to monitor your anticoagulant therapy.

thyroid medications. A larger dose of thyroid medication may be needed.

insulin. Monitor your blood sugar levels and discuss any unusual changes with your doctor.

tamoxifen. Chlorotrianisene should not be taken during therapy with tamoxifen.

Chlorotrianisene may also increase the effects of some medications. The following drugs may have increased or dangerous side effects if taken with chlorotrianisene:

tricyclic antidepressants such as amitriptyline (Elavil) and doxepin (Sinequan); other commonly used tricyclic antidepressants, including amoxapine (Ascendin), clomipramine (Anafranil), desipramine (Norpramin), imipramine (Tofranil), nortriptyline (Pamelor), and protriptyline (Vivactil); and

didanosine (Videx).

Before taking this medication, tell your doctor if you are taking any of the medicines listed above.

Other drugs may also affect chlorotrianisene. The effects of chlorotrianisene are decreased by

phenytoin (Dilantin) and ethotoin (Peganone),

carbamazepine (Tegretol),

phenobarbital (Solfoton, Luminal),

primidone (Mysoline), and

rifampin (Rifadin).

You may need larger doses of chlorotrianisene if you are taking any of the medicines listed above.

Drugs other than those listed here may also interact with chlorotrianisene. Talk to your doctor and pharmacist before taking any prescription or over-the-counter medicines.

More chlorotrianisene resources Chlorotrianisene Drug Interactions Chlorotrianisene Support Group 0 Reviews for Chlorotrianisene - Add your own review/rating Compare chlorotrianisene with other medications Menopausal Disorders Primary Ovarian Failure Prostate Cancer Where can I get more information? Your pharmacist has additional information about chlorotrianisene written for health professionals that you may read. What does my medication look like?

Chlorotrianisene is available with a prescription under the brand name Tace. Other brand or generic formulations may also be available. Ask your pharmacist any questions you have about this medication, especially if it is new to you.

Tace 12 mg--green, hard-gelatin capsules

Contraceptives

A drug may be classified by the chemical type of the active ingredient or by the way it is used to treat a particular condition. Each drug can be classified into one or more drug classes.

Contraceptives are used to prevent unwanted pregnancy. Hormonal contraceptives consist of one or more synthetic female sex hormones (estrogen and progestin or progestin only). These sex hormones prevent pregnancy by blocking the normal process of ovulation. They may also alter the lining of the uterus (endometrium) so that it is unable to support a fertilized egg and they change the mucus in the cervix so that it is hard for the sperm to travel hence conception is less likely should ovulation occur.

These hormones are either taken as regular doses in pill form (oral contraceptives), or are administered through the skin by means of a patch impregnated with hormones. They can also be given by three monthly injections of a long acting progestin, or by subcutaneous implants of progestin. They are also available as hormonal intrauterine devices and vaginal rings.

See also

Medical conditions associated with contraceptives:

Abnormal Uterine Bleeding Acne Amenorrhea Birth Control Emergency Contraception Endometrial Cancer Endometrial Hyperplasia, Prophylaxis Endometriosis Gonadotropin Inhibition Menstrual Disorders Ovarian Cysts Polycystic Ovary Syndrome Postmenopausal Symptoms Premenstrual Dysphoric Disorder Premenstrual Syndrome Prevention of Osteoporosis Renal Cell Carcinoma Drug List: Junel-1-5-30 Nordette Norinyl-1-35 Zeosa Plan-B Triphasil Ortho-Novum-1-35 Loestrin-1-20 Plan-B-One-Step Demulen Zarah Ovcon-35 Trivora Lybrel Low-Ogestrel-28 Necon-1-35 Ortho-Novum-7-7-7 Aranelle Gildess-Fe-1-5-0-03 Modicon Nexplanon Next-Choice Tri-Legest-Fe Ortho_Cyclen Lutera Ortho_Evra Junel-1-20 Seasonale Yasmin Femcon-Fe-Chewable-Tablets Lo-Ovral Mircette Desogen Lo-Loestrin-Fe Low-Ogestrel Nora-Be Microgestin-1-20 Camila Kelnor Mirena Nuvaring Portia Provera Aviane Quasense-Extended-Cycle Trinessa Jolessa Lo-Ovral-28 Mononessa Yaz Alesse Beyaz Cryselle-28 Kariva Levlen Ocella Depo-Provera-Contraceptive-Injectable Loestrin_24_Fe Microgestin-Fe-1-5-30 Apri Aygestin Implanon Zovia-1-35 Depo-Provera Femhrt Ortho-Tri-Cyclen Ortho-Tri-Cyclen-Lo Tri-Lo-Sprintec Levora Natazia Sronyx Junel-Fe-1-5-30 Junel-Fe-1-20 Tri-Sprintec Seasonique Sprintec Cyclessa Microgestin-Fe-1-20 Safyral Necon-7-7-7 Ortho-Cept Loseasonique Ortho-Micronor Gianvi Jolivette Reclipsen Errin Lessina Zovia Tri-Previfem Briellyn Nortrel-7-7-7 Velivet Ogestrel-28 Loestrin-Fe-1-20 Nortrel-1-35 Loestrin-21-1-20 Orsythia Triphasil-28 Altavera Amethia Amethia-Lo Amethyst Balziva Brevicon Camrese Caziant Cesia Cyclafem-1-35 Cyclafem-7-7-7 Depo-Subq-Provera-104-Injectable-Suspension-Subcutaneous Emoquette Enpresse Estrostep-Fe Generess-Fe Genora-1-35 Gildess-Fe-1-0-2 Jenest Jevantique Jinteli Leena Levlite Levonest Loestrin-21-1-5-30 Loestrin-Fe-1-5-30 Loryna Lunelle Microgestin-1-5-30 Necon-0-5-35 Necon-1-50 Necon-10-11 Nelova-0-5-35 Nor-Qd Norethin-1-35-E Norinyl-1-50 Norplant-System Nortrel-0-5-35 Ogestrel Ortho-Novum-1-50 Ovcon-35-Fe Ovcon-50 Preven-Ec Previfem Solia Syeda Tilia-Fe Tri-Legest Tri-Levlen Tri-Norinyl Trinessa-Lo Triphasil-21 Trivora-28 Vestura Zenchent Zenchent-Fe Zovia-1-50

Thiabendazole
Pronunciation: thye-a-BEN-da-zoleGeneric Name: ThiabendazoleBrand Name: Mintezol

Fosrenol
lanthanum carbonate Dosage Form: tablet, chewableFULL PRESCRIBING INFORMATION Indications and Usage for Fosrenol

Fosrenol is a phosphate binder indicated to reduce serum phosphate in patients with end stage renal disease (ESRD).

Management of elevated serum phosphorus levels in end stage renal disease patients usually includes all of the following: reduction in dietary intake of phosphate, removal of phosphate by dialysis and reduction of intestinal phosphate absorption with phosphate binders.

Fosrenol Dosage and Administration

 Divide the total daily dose of Fosrenol and take with or immediately after meals. The recommended initial total daily dose of Fosrenol is 1500 mg. Titrate the dose every 2-3 weeks until an acceptable serum phosphate level is reached. Monitor serum phosphate levels as needed during dose titration and on a regular basis thereafter.

In clinical studies of ESRD patients, Fosrenol doses up to 4500 mg were evaluated. Most patients required a total daily dose between 1500 mg and 3000 mg to reduce plasma phosphate levels to less than 6.0 mg/dL. Doses were generally titrated in increments of 750 mg/day.

 Chew or crush tablets completely before swallowing. Do not swallow intact tablets.

 Consider crushing tablets completely for patients with poor dentition.

Consider potential drug interactions when prescribing Fosrenol [see Drug Interactions (7)].

Dosage Forms and Strengths

Chewable Tablets: 500 mg, 750 mg, and 1000 mg.

Contraindications

 Bowel obstruction, ileus, and fecal impaction.

Warnings and Precautions Gastrointestinal Adverse Effects

There have been reports of serious cases of gastrointestinal obstruction, ileus, and fecal impaction reported in association with lanthanum, some requiring surgery or hospitalization.

Risk factors for gastrointestinal obstruction identified from post-marketing reports include alteration in gastrointestinal anatomy (e.g., history of gastrointestinal surgery, colon cancer), hypomotility disorders (e.g., constipation, ileus, diabetes) and concomitant medications (e.g., calcium channel blockers). Some cases were reported in patients with no history of gastrointestinal disease.

 Advise patients to chew the tablet completely to reduce the risk of serious adverse gastrointestinal events such as those described above.

Patients with acute peptic ulcer, ulcerative colitis, Crohn's disease or bowel obstruction were not included in Fosrenol clinical studies [see Contraindications (4)].

Diagnostic Tests

Fosrenol has radio-opaque properties and therefore may give the appearance typical of an imaging agent during abdominal X-ray procedures.

Adverse Reactions

Overall, the safety profile of Fosrenol has been studied in over 5200 subjects in completed clinical trials. The most common adverse reactions for Fosrenol were gastrointestinal events, such as nausea, vomiting, and abdominal pain and they generally abated over time with continued dosing.

Clinical Trials Experience

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

In double-blind, placebo-controlled studies where a total of 180 and 95 ESRD patients were randomized to Fosrenol and placebo, respectively, for 4-6 weeks of treatment, the most common reactions that were more frequent (>5% difference) in the Fosrenol group were nausea, vomiting, and abdominal pain (Table 1).

Table 1. Adverse Reactions* That Were More Common on Fosrenol in Placebo-Controlled, Double-Blind Studies With Treatment Periods of 4-6 Weeks Fosrenol

Metopirone Capsules 250 mg
1. Name Of The Medicinal Product

Metopirone® Capsules 250mg

2. Qualitative And Quantitative Composition

Metyrapone BP 250mg.

3. Pharmaceutical Form

Yellowish-white, oblong, opaque, soft gelatin capsules printed 'CIBA' on one side and 'LN' on the other in brown ink.

4. Clinical Particulars 4.1 Therapeutic Indications

A diagnostic aid in the differential diagnosis of ACTH-dependent Cushing's syndrome. The management of patients with Cushing's syndrome.

In conjunction with glucocorticosteroids in the treatment of resistant oedema due to increased aldosterone secretion in patients suffering from cirrhosis, nephrosis and congestive heart failure.

4.2 Posology And Method Of Administration

Adults:

The capsules should be taken with milk or after a meal, to minimise nausea and vomiting, which can lead to impaired absorption.

For use as a diagnostic aid: the patient must be hospitalised. Urinary 17-oxygenic steroid excretion is measured over 24 hours on each of 4 consecutive days. The first 2 days serve as a control period. On the third day, 750mg Metopirone (3 capsules) must be given at four-hourly intervals to give a total of 6 doses (ie 4.5g). Maximum urine steroid excretion may occur on the fourth day. If urinary steroid excretion increases in response to Metopirone, this suggests the high levels of circulatory cortisol are due to adrenocortical hyperplasia following excessive ACTH production rather than a cortisol-producing adrenal tumour.

For therapeutic use: for the management of Cushing's syndrome, the dosage must be adjusted to meet the patient's requirements; a daily dosage from 250mg to 6g may be required to restore normal cortisol levels.

For the treatment of resistant oedema: The usual daily dose of 3g (12 capsules) should be given in divided doses in conjunction with a glucocorticoid.

Children: Children should be given a smaller amount based upon 6 four-hourly doses of 15mg/kg, with a minimum dose of 250mg every four hours.

Elderly: Clinical evidence would indicate that no special dosage regimen is necessary.

4.3 Contraindications

Primary adrenocorticol insufficiency. Hypersensitivity to Metopirone or to any of the excipients. Pregnancy.

4.4 Special Warnings And Precautions For Use

In relation to use as a diagnostic aid: anticonvulsants (eg phenytoin, barbiturates), anti-depressants and neuroleptics (eg amitriptyline, chlorpromazine), hormones that affect the hypothalamo-pituitary axis and anti-thyroid agents may influence the results of the Metopirone test. If these drugs cannot be withdrawn, the necessity of carrying out the Metopirone test should be reviewed.

If adrenocortical or anterior pituitary function is more severely compromised than indicated by the results of the test, Metopirone may trigger transient adrenocortical insufficiency. This can be rapidly corrected by giving appropriate doses of corticosteroids.

Long-term treatment with Metopirone can cause hypertension as the result of excessive secretion of desoxycorticosterone.

The ability of the adrenal cortex to respond to exogenous ACTH should be demonstrated before Metopirone is employed as a test, as Metopirone may induce acute adrenal insufficiency in patients with reduced adrenal secretory capacity, as well as in patients with gross hypopituitarism.

Patients with liver cirrhosis often show a delayed response to Metopirone, due to liver damage delaying the metabolism of cortisol.

In cases of thyroid hypofunction, urinary steroid levels may rise very slowly, or not at all, in response to Metopirone.

4.5 Interaction With Other Medicinal Products And Other Forms Of Interaction

In some cases concomitant medication may affect the results of the Metopirone test (see Section 4.4, Special warnings and precautions for use).

4.6 Pregnancy And Lactation

No data are available from animal reproduction studies. Metopirone should not be administered during pregnancy since the drug can impair the biosynthesis of foetal-placental steroids. It is not known whether metyrapone passes into the breast milk, therefore nursing mothers should refrain from breast-feeding their infants during treatment with Metopirone.

4.7 Effects On Ability To Drive And Use Machines

Patients should be warned of the potential hazards of driving or operating machinery if they experience side effects such as dizziness and sedation.

4.8 Undesirable Effects

Gastrointestinal tract: Occasional: nausea, vomiting. Rare: abdominal pain.

Central nervous system: Occasional: dizziness, sedation, headache.

Cardiovascular system: Occasional: hypotension.

Skin: Rare: allergic skin reactions.

Endocrine system: Rare: hypoadrenalism, hirsutism.

4.9 Overdose

Signs and symptoms: The clinical picture of acute Metopirone poisoning is characterised by gastrointestinal symptoms and acute adrenocortical insufficiency. Laboratory findings: hyponatraemia, hypochloraemia, hyperkalaemia. In patients under treatment with insulin or oral antidiabetics, the signs and symptoms of acute poisoning with Metopirone may be aggravated or modified.

Treatment: There is no specific antidote. Gastric lavage and forced emesis should be employed to reduce the absorption of the drug. In addition to general measures, a large dose of hydrocortisone should be administered at once, together with iv saline and glucose. This should be repeated as necessary in accordance with the patient's clinical condition. For a few days, blood pressure and fluid and electrolyte balance should be monitored.

5. Pharmacological Properties 5.1 Pharmacodynamic Properties

Metopirone inhibits the enzyme responsible for the 11?-hydroxylation stage in the biosynthesis of cortisol and to a lesser extent, aldosterone. The fall in plasma concentration of circulating glucocorticoids stimulates ACTH secretion, via the feedback mechanism which accelerates steroid biosynthesis. As a result, 11-desoxycortisol, the precursor of cortisol, is released into the circulation, metabolised by the liver and excreted in the urine. Unlike cortisol, 11-desoxycortisol does not suppress ACTH secretion and its urinary metabolites may be measured.

These metabolites can easily be determined by measuring urinary 17-hydroxycorticosteroids (17-OHCS) or 17-ketogenic steroids (17-KGS). Metopirone is used as a diagnostic test on the basis of these properties, with plasma 11-desoxycortisol and urinary 17-OHCS measured as an index of pituitary ACTH responsiveness. Metopirone may also suppress biosynthesis of aldosterone, resulting in mild natriuresis.

5.2 Pharmacokinetic Properties

Metyrapone is rapidly absorbed and eliminated from the plasma. Peak plasma levels usually occur one hour after ingestion of Metopirone; after a dose of 750mg Metopirone, plasma drug levels average 3.7?g/ml. Plasma drug levels decrease to a mean value of 0.5?g/ml 4 hours after dosing. The half-life of elimination of Metopirone from the plasma is 20 to 26 minutes.

Metyrapol, the reduced form of metyrapone, is the main active metabolite. Eight hours after a single oral dose, the ratio of metyrapone to metyrapol in the plasma is 1:1.5. Metyrapol takes about twice as long as metyrapone to be eliminated in the plasma.

Seventy-two hours after a first daily dose of 4.5g Metopirone (750mg every 4 hours), 5.3% of the total dose was excreted in the urine as metyrapone (9.2% in free form and 90.8% conjugated with glucuronic acid), and 38.5% in the form of metyrapol (8.1% in free form and 91.9% conjugated with glucuronic acid).

5.3 Preclinical Safety Data

There are no pre-clinical data of relevance to the prescriber which are additional to those already included in other sections of the Summary of Product Characteristics.

6. Pharmaceutical Particulars 6.1 List Of Excipients

Capsule contents: Glycerin, polyethylene glycol 400, polyethylene glycol 4000 and water. Capsule shell: Sodium ethylparaben, ethyl vanillin, gelatin, glycerin 85%, p-methoxy acetophenone, sodium propylparaben and titanium oxide (E171).

6.2 Incompatibilities

None stated.

6.3 Shelf Life

3 years

6.4 Special Precautions For Storage

Protect from moisture and heat. Store below 30°C.

6.5 Nature And Contents Of Container

High density polyethylene bottles of 100 capsules.

6.6 Special Precautions For Disposal And Other Handling

None stated.

Administrative Details

7. Marketing Authorisation Holder

Alliance Pharmaceuticals Ltd

Avonbridge House

Bath Road

Chippenham

Wiltshire

SN15 2BB

8. Marketing Authorisation Number(S)

PL16853/0010

9. Date Of First Authorisation/Renewal Of The Authorisation

June 1998

10. Date Of Revision Of The Text

30th June 2009

Legal status

POM

Alliance, Alliance Pharmaceuticals and associated devices are registered Trademarks of Alliance Pharmaceuticals Ltd.

Solu-Medrol
Dosage Form: injection, powder, for solutionSolu-Medrol® (methylprednisolone sodium succinate for injection, USP)

For Intravenous or Intramuscular Administration

Solu-Medrol Description

Solu-Medrol Sterile Powder is an anti-inflammatory glucocorticoid, which contains methylprednisolone sodium succinate as the active ingredient. Methylprednisolone sodium succinate, USP, is the sodium succinate ester of methylprednisolone, and it occurs as a white, or nearly white, odorless hygroscopic, amorphous solid. It is very soluble in water and in alcohol; it is insoluble in chloroform and is very slightly soluble in acetone.

The chemical name for methylprednisolone sodium succinate is pregna-1,4-diene-3,20-dione,21-(3-carboxy-1-oxopropoxy)-11,17-dihydroxy-6-methyl-monosodium salt, (6?, 11?), and the molecular weight is 496.53. The structural formula is represented below:

Methylprednisolone sodium succinate is soluble in water; it may be administered in a small volume of diluent and is well suited for intravenous use in situations where high blood levels of methylprednisolone are required rapidly.

Solu-Medrol is available in preservative-free formulations:

40 mg Act-O-Vial System (Single-Use Vial)

Each mL (when mixed) contains methylprednisolone sodium succinate equivalent to 40 mg methylprednisolone; also 1.6 mg monobasic sodium phosphate anhydrous; 17.46 mg dibasic sodium phosphate dried; and 25 mg lactose hydrous.

125 mg Act-O-Vial System (Single-Use Vial)

Each 2 mL (when mixed) contains methylprednisolone sodium succinate equivalent to 125 mg methylprednisolone; also 1.6 mg monobasic sodium phosphate anhydrous; and 17.4 mg dibasic sodium phosphate dried.

When necessary, the pH of each formula was adjusted with sodium hydroxide so that the pH of the reconstituted solution is within the USP specified range of 7 to 8 and the tonicities are, for the 40 mg per mL solution, 0.50 osmolar; and for the 125 mg per 2 mL, 0.40 osmolar. (Isotonic saline = 0.28 osmolar).

IMPORTANT — Use only the accompanying diluent

Leuprolide Suspension
Pronunciation: LOO-proe-lideGeneric Name: LeuprolideBrand Name: Lupron Depot

Indater

Indater may be available in the countries listed below.

Ingredient matches for Indater Indapamide

Indapamide is reported as an ingredient of Indater in the following countries:

Romania

International Drug Name Search

Deca-Durabolin 50mg / ml
1. Name Of The Medicinal Product

Deca Durabolin 50mg/ml

2. Qualitative And Quantitative Composition

Each ml of Deca Durabolin contains 50mg nandrolone decanoate.

3. Pharmaceutical Form

Solution for injection.

4. Clinical Particulars 4.1 Therapeutic Indications

For use in osteoporosis in post-menopausal women.

Established osteoporosis should have been diagnosed by the following

parameters:

i) crush or wedge fractures of the vertebrae

ii) other osteoporotic fractures

iii) established reduction in bone mineral content as measured by accepted BMC measurements.

4.2 Posology And Method Of Administration

Dosage

Post-menopausal women

50 mg every three weeks.

The duration of treatment depends on the clinical response and the possible occurrence of side-effects.

We would recommend that the effectiveness of therapy be monitored with the appropriate methods for osteoporosis on a 6-12 monthly basis.

Children

There are no recommendations for use in children.

Administration

Deep intramuscular injection

4.3 Contraindications

Pregnancy

Breast-feeding

Porphyria

Allergies to any of the components

Known or suspected carcinoma of prostate or mammary carcinoma in the male

4.4 Special Warnings And Precautions For Use

If signs of virilisation develop, discontinuation of the treatment should be considered.

Patients, especially the elderly, with the following conditions should be monitored:

• latent or overt cardiac failure, renal dysfunction, hypertension, epilepsy or migraine (or a history of these conditions), since anabolic steroids may occasionally induce sodium and water retention;

• incomplete statural growth, since anabolic steroids in high dosages may accelerate epiphyseal closure;

• skeletal metastases, since anabolic steroids may induce hypercalcaemia and hypercalciuria in these patients;

• liver dysfunction - caution should be used in patients with severe hepatic impairment and Deca Durabolin 50mg/ml should only be used if the benefits outweigh the risks.

• diabetes mellitus

Deca Durabolin 50mg/ml contains Arachis oil (peanut oil) and should not be taken / applied by patients known to be allergic to peanut. As there is a possible relationship between allergy to peanut and allergy to Soya, patients with Soya allergy should also avoid Deca Durabolin 50mg/ml.

4.5 Interaction With Other Medicinal Products And Other Forms Of Interaction

Anabolic steroids may improve glucose tolerance and decrease the need for insulin or other antidiabetic drugs in diabetics.

4.6 Pregnancy And Lactation

Deca-Durabolin is contra-indicated during pregnancy because of possible masculinisation of the foetus. There are insufficient data on the use of this medicine during breast-feeding to assess potential harm to the infant or a possible influence on milk production.

4.7 Effects On Ability To Drive And Use Machines

None known.

4.8 Undesirable Effects

Deca-Durabolin at the recommended dosages is unlikely to produce virilising effects. High dosages, prolonged treatment and/or too frequent administration may cause:

• Virilisation which appears in sensitive women as hoarseness, acne, hirsutism and increase of libido; in prepubertal boys as an increased frequency of erections and phallic enlargement, and in girls as an increase of pubic hair and clitoral hypertrophy. Hoarseness may be the first symptom of vocal change which may end in long-lasting, sometimes irreversible deepening of the voice;

• Amenorrhoea and inhibition of spermatogenesis;

• Premature epiphyseal closure;

• Sodium and water retention.

Abnormal liver function tests have been reported in patients treated with (high doses) of Deca-Durabolin.

Liver tumours have been reported occasionally on prolonged treatment with orally active C17-alpha alkylated anabolic steroids. A relationship between liver tumours and non-C17-alkylated injectable steroids, such as nandrolone esters, appears to be highly unlikely, but cannot be absolutely excluded.

4.9 Overdose

The acute toxicity of nandrolone decanoate in animals is very low. There are no reports of acute overdosage with Deca-Durabolin in the human.

5. Pharmacological Properties 5.1 Pharmacodynamic Properties

Nandrolone is chemically related to testosterone and shows enhanced anabolic and a reduced androgenic activity.

In humans Deca-Durabolin has been shown to positively influence calcium metabolism and to increase bone mass in osteoporosis.

Androgenic effects (e.g. virilisation) are relatively uncommon at the recommended dosages. Nandrolone lacks the C17 alpha-alkyl group which is associated with the occurrence of liver dysfunction and cholestasis.

5.2 Pharmacokinetic Properties

Nandrolone decanoate is slowly released from the injection site into the blood with a half-life of 6 days. The ester is rapidly hydrolysed to nandrolone in the blood with a half-life of one hour or less. The half-life for the combined process of hydrolysis of nandrolone decanoate and of distribution and elimination of nandrolone is 4.3 hours.

Nandrolone is metabolised by the liver. 19-norandrosterone, 19-noretiocholanolone and 19-norepiandrosterone have been identified as metabolites in the urine. It is not known whether these metabolites display a pharmacological action.

5.3 Preclinical Safety Data

Not applicable.

6. Pharmaceutical Particulars 6.1 List Of Excipients

Benzyl alcohol

Arachis oil

6.2 Incompatibilities

None known

6.3 Shelf Life

1 ml ampoule 60 months.

6.4 Special Precautions For Storage

Do not store above 30°C

Do not refrigerate or freeze.

Keep in the container in the outer carton.

6.5 Nature And Contents Of Container

1 x 1ml ampoules

3 x 1ml ampoules

6 x 1ml ampoules

6.6 Special Precautions For Disposal And Other Handling

Not applicable.

7. Marketing Authorisation Holder

Organon Laboratories Limited,

Cambridge Science Park,

Milton Road,

Cambridge, CB4 0FL

8. Marketing Authorisation Number(S)

PL0065/5063R

9. Date Of First Authorisation/Renewal Of The Authorisation

28/2/73 / 27/04/05

10. Date Of Revision Of The Text

20 April 2010

11 Legal Category

Prescription Only Medicine

Ref:USDD50v4.2

RA 1220 GB S1 (ref 1.0)

DecaDurabolin/UK/04-10/1

Tetrahydrozoline/Zinc Drops
Pronunciation: te-tra-hye-DROZ-oh-leen/ZINKGeneric Name: Tetrahydrozoline/ZincBrand Name: Examples include Altazine Irritation Relief and Visine AC

Jasochlor

Jasochlor may be available in the countries listed below.

Ingredient matches for Jasochlor Chloroquine

Chloroquine phosphate (a derivative of Chloroquine) is reported as an ingredient of Jasochlor in the following countries:

Bangladesh

International Drug Name Search

Voltaren Topical

Generic Name: diclofenac (Topical route)

dye-KLOE-fen-ak

Topical route(Gel/Jelly;Solution)

NSAIDs may cause an increased risk of serious cardiovascular thrombotic events, myocardial infarction, and stroke, which can be fatal. This risk may be increased in patients with cardiovascular disease or risk factors for cardiovascular disease. Diclofenac is contraindicated for the treatment of peri-operative pain in the setting of CABG surgery. NSAIDs can also cause an increased risk of serious gastrointestinal adverse events especially in the elderly, including bleeding, ulceration, and perforation of the stomach or intestines, which can be fatal .

Topical application route(Patch, Extended Release)

NSAIDs may cause an increased risk of serious cardiovascular thrombotic events, myocardial infarction, and stroke, which can be fatal. This risk may increase with duration of use and in patients with cardiovascular disease or risk factors for cardiovascular disease. Diclofenac patch is contraindicated in the peri-operative setting of coronary artery bypass graft (CABG) surgery. NSAIDs can also cause an increased risk of serious gastrointestinal adverse events including bleeding, ulceration, and perforation of the stomach or intestines, which can be fatal and may occur at any time and without warning. Elderly patients are at greater risk of serious gastrointestinal events .

Commonly used brand name(s)

In the U.S.

Flector Pennsaid Solaraze Voltaren

Available Dosage Forms:

Gel/Jelly Solution Patch, Extended Release

Therapeutic Class: Anti-Inflammatory

Pharmacologic Class: NSAID

Chemical Class: Acetic Acid (class)

Uses For Voltaren

Diclofenac is a nonsteroidal anti-inflammatory drug (NSAID) used to treat pain and other symptoms of arthritis of the joints (e.g., osteoarthritis), such as inflammation, swelling, stiffness, and joint pain. However, this medicine does not cure osteoarthritis and will help you only as long as you continue to use it.

Diclofenac is also used to treat actinic keratosis, a skin problem that may become cancerous if not treated. The exact way that topical diclofenac helps this condition is unknown.

Diclofenac topical patch is used to treat acute pain caused by minor strains, sprains, and contusions (bruises).

This medicine is available only with your doctor's prescription.

Before Using Voltaren

In deciding to use a medicine, the risks of taking the medicine must be weighed against the good it will do. This is a decision you and your doctor will make. For this medicine, the following should be considered:

Allergies

Tell your doctor if you have ever had any unusual or allergic reaction to this medicine or any other medicines. Also tell your health care professional if you have any other types of allergies, such as to foods, dyes, preservatives, or animals. For non-prescription products, read the label or package ingredients carefully.

Pediatric

Appropriate studies have not been performed on the relationship of age to the effects of diclofenac in the pediatric population. Safety and efficacy have not been established.

Geriatric

Appropriate studies performed to date have not demonstrated geriatric-specific problems that would limit the usefulness of diclofenac in the elderly. However, elderly patients are more likely to have age-related kidney problems, which may require caution and an adjustment in the dose for patients receiving diclofenac.

Pregnancy Pregnancy Category Explanation 1st Trimester C Animal studies have shown an adverse effect and there are no adequate studies in pregnant women OR no animal studies have been conducted and there are no adequate studies in pregnant women. 2nd Trimester C Animal studies have shown an adverse effect and there are no adequate studies in pregnant women OR no animal studies have been conducted and there are no adequate studies in pregnant women. 3rd Trimester D Studies in pregnant women have demonstrated a risk to the fetus. However, the benefits of therapy in a life threatening situation or a serious disease, may outweigh the potential risk. Breast Feeding

There are no adequate studies in women for determining infant risk when using this medication during breastfeeding. Weigh the potential benefits against the potential risks before taking this medication while breastfeeding.

Interactions with Medicines

Although certain medicines should not be used together at all, in other cases two different medicines may be used together even if an interaction might occur. In these cases, your doctor may want to change the dose, or other precautions may be necessary. When you are taking this medicine, it is especially important that your healthcare professional know if you are taking any of the medicines listed below. The following interactions have been selected on the basis of their potential significance and are not necessarily all-inclusive.

Using this medicine with any of the following medicines is not recommended. Your doctor may decide not to treat you with this medication or change some of the other medicines you take.

Ketorolac Pentoxifylline

Using this medicine with any of the following medicines is usually not recommended, but may be required in some cases. If both medicines are prescribed together, your doctor may change the dose or how often you use one or both of the medicines.

Abciximab Ardeparin Argatroban Beta Glucan Bivalirudin Certoparin Cilostazol Citalopram Clopidogrel Clovoxamine Dabigatran Etexilate Dalteparin Danaparoid Desirudin Dipyridamole Enoxaparin Escitalopram Femoxetine Flesinoxan Fluoxetine Fluvoxamine Fondaparinux Ginkgo Heparin Lepirudin Methotrexate Nadroparin Nefazodone Parnaparin Paroxetine Pemetrexed Protein C Reviparin Rivaroxaban Sertraline Sibutramine Tacrolimus Ticlopidine Tinzaparin Tirofiban Vilazodone Zimeldine

Using this medicine with any of the following medicines may cause an increased risk of certain side effects, but using both drugs may be the best treatment for you. If both medicines are prescribed together, your doctor may change the dose or how often you use one or both of the medicines.

Acebutolol Acetohexamide Alacepril Alprenolol Amiloride Arotinolol Atenolol Azilsartan Medoxomil Azosemide Befunolol Bemetizide Benazepril Bendroflumethiazide Benzthiazide Betaxolol Bevantolol Bisoprolol Bopindolol Bucindolol Bumetanide Bupranolol Buthiazide Candesartan Cilexetil Canrenoate Captopril Carteolol Carvedilol Celiprolol Chlorothiazide Chlorpropamide Chlorthalidone Cilazapril Ciprofloxacin Clopamide Cyclopenthiazide Cyclosporine Delapril Desvenlafaxine Dilevalol Duloxetine Enalaprilat Enalapril Maleate Eprosartan Esmolol Ethacrynic Acid Fosinopril Furosemide Gliclazide Glimepiride Glipizide Gliquidone Glyburide Hydrochlorothiazide Hydroflumethiazide Imidapril Indapamide Irbesartan Labetalol Landiolol Levobetaxolol Levobunolol Lisinopril Lithium Losartan Mepindolol Methyclothiazide Metipranolol Metolazone Metoprolol Milnacipran Moexipril Nadolol Nebivolol Nipradilol Olmesartan Medoxomil Oxprenolol Penbutolol Pentopril Perindopril Pindolol Piretanide Polythiazide Propranolol Quinapril Ramipril Sotalol Spirapril Spironolactone Talinolol Tasosartan Telmisartan Temocapril Tertatolol Timolol Tolazamide Tolbutamide Torsemide Trandolapril Triamterene Trichlormethiazide Valsartan Venlafaxine Voriconazole Xipamide Zofenopril Interactions with Food/Tobacco/Alcohol

Certain medicines should not be used at or around the time of eating food or eating certain types of food since interactions may occur. Using alcohol or tobacco with certain medicines may also cause interactions to occur. Discuss with your healthcare professional the use of your medicine with food, alcohol, or tobacco.

Other Medical Problems

The presence of other medical problems may affect the use of this medicine. Make sure you tell your doctor if you have any other medical problems, especially:

Anemia or Bleeding problems or Blood clots or Congestive heart failure or Edema (fluid retention or body swelling) or Heart attack, history of or Heart disease or Hypertension (high blood pressure) or Kidney disease, mild to moderate or Stomach ulcers or bleeding, history of or Stroke, history of—Use with caution. May make these conditions worse. Aspirin-sensitive asthma or Aspirin (or other NSAIDs) sensitivity, history of or Kidney disease, severe—Should not be used in patients with these conditions. Damaged or non-intact skin caused by skin diseases (e.g., exudative dermatitis, eczema, infection lesions), burns, or wounds (for skin patch only)—Should not be used in patients with this condition. Heart surgery (e.g., coronary artery bypass graft [CABG] surgery)—Should not be used to relieve pain right before or after the surgery. Liver disease—Use with caution. The effects may be increased because of slower removal of the medicine from the body. Proper Use of diclofenac

This section provides information on the proper use of a number of products that contain diclofenac. It may not be specific to Voltaren. Please read with care.

Keep using this medicine for the full time of treatment. However, do not use this medicine more often or for a longer time than your doctor ordered. This medicine is not for long-term use.

Diclofenac may cause redness, soreness, scaling, and peeling of the affected skin. Do not stop using this medicine without first checking with your doctor. If the reaction is very uncomfortable, check with your doctor.

This medicine comes with a Medication Guide and patient instructions. Read and follow these instructions carefully. Ask your doctor or pharmacist if you have any questions.

Use only the brand of this medicine that your doctor prescribed. Different brands may not work the same way.

To use the topical gel:

Wash your hands before and after using this medicine. Apply the medicine very carefully to clean, dry skin, and avoid getting any in your eyes, nose, or mouth. Do not apply this medicine to areas with broken skin or open wounds, infection, or severely peeling skin. Apply enough medicine each time to cover the entire affected area. Do not use heating pads or cover the treated area with a bandage unless your doctor has told you to. Do not use cosmetics (e.g., makeup or sunscreens) or other skin care products on the same skin areas where you have applied this medicine. After applying this medicine, do not shower, bathe, or wash the affected area for at least one hour. Wait at least 10 minutes before covering the treated skin with gloves or clothing.

To use the skin patch:

Use this medicine exactly as directed by your doctor. It will work only if applied correctly. Wash your hands with soap and water before and after applying a patch. Do not touch your eyes until after you have washed your hands. If it gets into your eyes, wash the eyes right away with water or saline. If eye irritation persists for more than one hour, call your doctor. Apply the patch right away after removing it from the protective pouch. Do not cut it into smaller pieces and do not touch the sticky surface of the patch. Apply the patch to a clean, dry, intact skin area. Choose an area with little or no hair and free of scars, cuts, or irritation. Avoid putting the patch on areas where it could be rubbed off by tight clothing. Press the patch firmly in place with your fingertips to make sure that the edges of the patch stick well. If the patch begins to peel off, the edges of the patch may be taped down. If the patch still peels off, it may be used with a mesh netting sleeve (e.g., Curad® Hold Tite™, Surgilast® Tubular Elastic Dressing) to hold the patch applied to the ankles, knees, or elbows. The mesh netting sleeve must not be occlusive and must allow air to pass through. Do not use the patch when you take a bath or shower.

To help you remember to use your medicine, try to get into the habit of using it at regular times. If you are using the transdermal system (skin patch), try to change it at the same time and day of the week.

Dosing

The dose of this medicine will be different for different patients. Follow your doctor's orders or the directions on the label. The following information includes only the average doses of this medicine. If your dose is different, do not change it unless your doctor tells you to do so.

The amount of medicine that you take depends on the strength of the medicine. Also, the number of doses you take each day, the time allowed between doses, and the length of time you take the medicine depend on the medical problem for which you are using the medicine.

For topical dosage form (gel): For actinic keratosis: Adults—Apply to affected skin area two times per day. Children—Use and dose must be determined by your doctor. For osteoarthritis of the hands, elbows, or wrists: Adults—Apply 2 grams to the affected skin areas four times per day (a total of 8 grams each day). However, the total dose should not exceed 32 grams per day over all affected joints. Children—Use and dose must be determined by your doctor. For osteoarthritis of the knees, ankles, or feet: Adults—Apply 4 grams to the affected skin areas four times per day (a total of 16 grams each day). However, the total dose should not exceed 32 grams per day over all affected joints. Children—Use and dose must be determined by your doctor. For transdermal dosage form (skin patch): For acute pain: Adults—One patch applied to the painful area two times per day. Children—Use and dose must be determined by your doctor. Missed Dose

If you miss a dose of this medicine, take it as soon as possible. However, if it is almost time for your next dose, skip the missed dose and go back to your regular dosing schedule. Do not double doses.

If you forget to wear or change a patch, put one on as soon as you can. If it is almost time to put on your next patch, wait until then to apply a new patch and skip the one you missed. Do not apply extra patches to make up for a missed dose.

Storage

Store the medicine in a closed container at room temperature, away from heat, moisture, and direct light. Keep from freezing.

Keep out of the reach of children.

Do not keep outdated medicine or medicine no longer needed.

Ask your healthcare professional how you should dispose of any medicine you do not use.

After removing a used patch, fold the patch in half with the sticky sides together. Make sure to dispose of it out of the reach of children and pets.

Precautions While Using Voltaren

It is very important that your doctor check your progress at regular visits. This will allow your doctor to make sure this medicine is working properly and to decide if you should continue to use it. Blood and urine tests may be needed to check for unwanted effects.

This medicine may raise your risk of having a heart attack or stroke. This is more likely in people who already have heart disease. People who use this medicine for a long time might also have a higher risk.

This medicine may cause bleeding in your stomach or intestines. These problems can happen without warning signs. This is more likely if you have had a stomach ulcer in the past, if you smoke or drink alcohol regularly, are over 60 years of age, are in poor health, or are using certain other medicines (such as a steroid medicine or a blood thinner).

Serious skin reactions can occur during treatment with this medicine. Check with your doctor right away if you have any of the following symptoms while using this medicine: blistering, peeling, loosening of the skin; chills; cough; diarrhea; fever; itching; joint or muscle pain; red skin lesions; sore throat sores, ulcers, or white spots in the mouth or on the lips; or unusual tiredness or weakness.

Some possible warning signs of serious side effects that can occur during treatment with this medicine may include black, tarry stools; decreased urination; severe stomach pain; skin rash; swelling of the face, fingers, feet, or lower legs; unusual bleeding or bruising; unusual weight gain; vomiting of blood or material that looks like coffee grounds; or yellow skin or eyes. Also, signs of serious heart problems could occur such as chest pain, tightness in the chest, fast or irregular heartbeat, unusual flushing or warmth of skin, weakness, or slurring of speech. Stop using this medicine and check with your doctor immediately if you notice any of these warning signs.

This medicine may also cause a serious type of allergic reaction called anaphylaxis. Although this is rare, it may occur more often in patients who are allergic to aspirin or to any of the nonsteroidal anti-inflammatory drugs (NSAIDs). Anaphylaxis can be life-threatening and requires immediate medical attention. The most serious signs of this reaction are very fast or irregular breathing, gasping for breath, wheezing, or fainting. Other signs may include changes in color of the skin of the face; very fast but irregular heartbeat or pulse; hive-like swellings on the skin; and puffiness or swelling of the eyelids or around the eyes. If these effects occur, get emergency help at once.

Using this medicine while you are pregnant can harm your unborn baby. If you think you have become pregnant while using this medicine, tell your doctor right away. Do not use this medicine during the later part of a pregnancy unless your doctor tells you to.

If your symptoms become worse, check with your doctor.

While using this medicine, your skin may become more sensitive to sunlight than usual, and too much sunlight may increase the effects of the medicine. During this period of time:

Stay out of direct sunlight, especially between the hours of 10:00 a.m. and 3:00 p.m., if possible. Wear protective clothing, including a hat and sunglasses. Do not use a sunlamp or tanning bed or booth. Make sure you have discussed the use of a sun block product with your doctor.

If you have a severe reaction from the sun, check with your doctor.

Before having any kind of surgery or medical tests, tell your doctor that you are using this medicine. It may be necessary for you to stop treatment for awhile, or to change to a different nonsteroidal antiinflammatory drug before your procedure.

Do not take other medicines unless they have been discussed with your doctor. This includes prescription or nonprescription (over-the-counter [OTC]) medicines and herbal or vitamin supplements.

Voltaren Side Effects

Along with its needed effects, a medicine may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

Check with your doctor immediately if any of the following side effects occur:

More common Application site reactions, including skin rash; pain, tingling, or burning sensation flu-like syndrome (body ache, headache, fever, with or without chills) itching skin Less common or rare Application site reactions, including swelling; increased skin sensitivity; itching, redness, or pain caused by reaction from exposure to sun blood in the urine cough decrease in body movement dry, itching, or burning eyes eye pain fever headaches, including migraines high blood pressure increased sensitivity of the eyes to light infection nasal congestion pain or tenderness around the eyes and cheekbones redness or swelling of the eyes shortness of breath skin rash other than at the application site sore throat tightness in the chest troubled breathing ulcers or sores on the skin, other than at the application site wheezing

Some side effects may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects. Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:

More common Burning skin dry skin red skin scaly skin thickened skin tingling skin Less common Acne back pain belching bleeding skin chest pain diarrhea heartburn indigestion joint pain lack or loss of strength loss or thinning of the hair muscle pain neck pain runny nose stomach upset or pain

Other side effects not listed may also occur in some patients. If you notice any other effects, check with your healthcare professional.

Call your doctor for medical advice about side effects. You may report side effects to the FDA at 1-800-FDA-1088.

The information contained in the Thomson Reuters Micromedex products as delivered by Drugs.com is intended as an educational aid only. It is not intended as medical advice for individual conditions or treatment. It is not a substitute for a medical exam, nor does it replace the need for services provided by medical professionals. Talk to your doctor, nurse or pharmacist before taking any prescription or over the counter drugs (including any herbal medicines or supplements) or following any treatment or regimen. Only your doctor, nurse, or pharmacist can provide you with advice on what is safe and effective for you.

The use of the Thomson Reuters Healthcare products is at your sole risk. These products are provided "AS IS" and "as available" for use, without warranties of any kind, either express or implied. Thomson Reuters Healthcare and Drugs.com make no representation or warranty as to the accuracy, reliability, timeliness, usefulness or completeness of any of the information contained in the products. Additionally, THOMSON REUTERS HEALTHCARE MAKES NO REPRESENTATION OR WARRANTIES AS TO THE OPINIONS OR OTHER SERVICE OR DATA YOU MAY ACCESS, DOWNLOAD OR USE AS A RESULT OF USE OF THE THOMSON REUTERS HEALTHCARE PRODUCTS. ALL IMPLIED WARRANTIES OF MERCHANTABILITY AND FITNESS FOR A PARTICULAR PURPOSE OR USE ARE HEREBY EXCLUDED. Thomson Reuters Healthcare does not assume any responsibility or risk for your use of the Thomson Reuters Healthcare products.

More Voltaren Topical resources Voltaren Topical Use in Pregnancy & Breastfeeding Voltaren Topical Drug Interactions Voltaren Topical Support Group 83 Reviews for Voltaren Topical - Add your own review/rating Pennsaid Consumer Overview Pennsaid Solution MedFacts Consumer Leaflet (Wolters Kluwer) Pennsaid Prescribing Information (FDA) Solaraze Prescribing Information (FDA) Solaraze Gel MedFacts Consumer Leaflet (Wolters Kluwer) Solaraze topical Monograph (AHFS DI) Compare Voltaren Topical with other medications Actinic Keratosis Osteoarthritis Pain

paclitaxel Intravenous

pak-li-TAX-el

Intravenous route(Solution)

Anaphylaxis and severe hypersensitivity reactions characterized by dyspnea and hypotension requiring treatment, angioedema, and generalized urticaria have occurred in clinical trials. Fatal reactions have occurred in patients despite premedication and all patients should be pretreated with corticosteroids, diphenhydramine, and H(2) antagonists. Patients who experience severe hypersensitivity reactions to paclitaxel should not be rechallenged with the drug. Paclitaxel therapy should not be given to patients with solid tumors who have baseline neutrophil counts of less than 1500 cells/mm(3) and should not be given to patients with AIDS-related Kaposi's sarcoma if the baseline neutrophil count is less than 1000 cells/mm(3). Monitor peripheral blood cell counts frequently .

Commonly used brand name(s)

In the U.S.

Nov-Onxol Onxol Paclitaxel Novaplus Taxol

Available Dosage Forms:

Solution

Therapeutic Class: Antineoplastic Agent

Pharmacologic Class: Mitotic Inhibitor

Uses For paclitaxel

Paclitaxel injection is used to treat advanced cancer of the ovaries, breast, non-small cell lung cancer, and Kaposi sarcoma. Kaposi sarcoma is a cancer of the skin and mucous membranes that is commonly found in patients with acquired immunodeficiency syndrome (AIDS).

Paclitaxel belongs to the group of medicines called antineoplastics. It interferes with the growth of cancer cells, which are eventually destroyed. Since the growth of normal body cells may also be affected, other unwanted effects will also occur. Some of these may be serious and must be reported to your doctor. Other effects may not be serious but may cause concern. Some effects may not occur until months or years after the medicine is used.

Before you begin treatment with paclitaxel, you and your doctor should talk about the good paclitaxel will do as well as the risks of using it.

paclitaxel is to be administered only by or under the immediate supervision of your doctor.

Once a medicine has been approved for marketing for a certain use, experience may show that it is also useful for other medical problems. Although these uses are not included in product labeling, paclitaxel is used in certain patients with the following medical conditions:

Cancer of the bladder. Cancer of the cervix. Cancer of the endometrium. Cancer of the esophagus. Cancer of the fallopian tube or lining of the abdomen (spreading from the ovary). Cancers of the head and neck. Cancer of the prostate. Cancer of the stomach Cancer of the testes. Cancer of unknown primary site. Small cell lung cancer (a certain type found in the tissues of the lungs). Before Using paclitaxel

In deciding to use a medicine, the risks of taking the medicine must be weighed against the good it will do. This is a decision you and your doctor will make. For paclitaxel, the following should be considered:

Allergies

Tell your doctor if you have ever had any unusual or allergic reaction to paclitaxel or any other medicines. Also tell your health care professional if you have any other types of allergies, such as to foods, dyes, preservatives, or animals. For non-prescription products, read the label or package ingredients carefully.

Pediatric

Appropriate studies have not been performed on the relationship of age to the effects of paclitaxel injection in the pediatric population. Safety and efficacy have not been established.

Geriatric

Appropriate studies performed to date have not demonstrated geriatric-specific problems that would limit the usefulness of paclitaxel injection in the elderly. However, elderly patients are more likely to have unwanted side effects (e.g., heart disease, bone marrow problems, and nerve problems), which may require caution in patients receiving paclitaxel injection.

Pregnancy Pregnancy Category Explanation All Trimesters D Studies in pregnant women have demonstrated a risk to the fetus. However, the benefits of therapy in a life threatening situation or a serious disease, may outweigh the potential risk. Breast Feeding

There are no adequate studies in women for determining infant risk when using this medication during breastfeeding. Weigh the potential benefits against the potential risks before taking this medication while breastfeeding.

Interactions with Medicines

Although certain medicines should not be used together at all, in other cases two different medicines may be used together even if an interaction might occur. In these cases, your doctor may want to change the dose, or other precautions may be necessary. When you are receiving paclitaxel, it is especially important that your healthcare professional know if you are taking any of the medicines listed below. The following interactions have been selected on the basis of their potential significance and are not necessarily all-inclusive.

Using paclitaxel with any of the following medicines is not recommended. Your doctor may decide not to treat you with this medication or change some of the other medicines you take.

Rotavirus Vaccine, Live

Using paclitaxel with any of the following medicines is usually not recommended, but may be required in some cases. If both medicines are prescribed together, your doctor may change the dose or how often you use one or both of the medicines.

Adenovirus Vaccine Type 4, Live Adenovirus Vaccine Type 7, Live Aprepitant Bacillus of Calmette and Guerin Vaccine, Live Bexarotene Cisplatin Deferasirox Doxorubicin Hydrochloride Ethinyl Estradiol Fosaprepitant Infliximab Influenza Virus Vaccine, Live Measles Virus Vaccine, Live Mumps Virus Vaccine, Live Pazopanib Rotavirus Vaccine, Live Rubella Virus Vaccine, Live Smallpox Vaccine St John's Wort Testosterone Tretinoin Typhoid Vaccine Valspodar Varicella Virus Vaccine Yellow Fever Vaccine

Using paclitaxel with any of the following medicines may cause an increased risk of certain side effects, but using both drugs may be the best treatment for you. If both medicines are prescribed together, your doctor may change the dose or how often you use one or both of the medicines.

Dalfopristin Doxorubicin Hydrochloride Liposome Epirubicin Fosphenytoin Lapatinib Phenytoin Quinupristin Interactions with Food/Tobacco/Alcohol

Certain medicines should not be used at or around the time of eating food or eating certain types of food since interactions may occur. Using alcohol or tobacco with certain medicines may also cause interactions to occur. Discuss with your healthcare professional the use of your medicine with food, alcohol, or tobacco.

Other Medical Problems

The presence of other medical problems may affect the use of paclitaxel. Make sure you tell your doctor if you have any other medical problems, especially:

Bradycardia (slow heart rate) or Heart rhythm problems or Hypertension (high blood pressure) or Hypotension (low blood pressure) or Peripheral neuropathy (pain, numbness, or tingling of hands, arms, legs, or feet)—Use with caution. May make these conditions worse. Infection—May decrease your body's ability to fight an infection. Liver disease—Use with caution. The effects may be increased because of slower removal of the medicine from the body. Neutropenia, severe (very low white blood cells)—Should not be used in patients with this condition. Proper Use of paclitaxel

Medicines used to treat cancer are very strong and can have many unwanted effects. Before receiving paclitaxel, you and your doctor should talk about the good paclitaxel will do as well as the risks of using it. .

A doctor or other trained health professional will give you paclitaxel in a hospital or cancer treatment center. paclitaxel is given through a needle placed in one of your veins.

paclitaxel is usually given every 3 weeks and is used together with other cancer medicines, such as cisplatin or doxorubicin.

You may also receive other medicines to help prevent allergic reactions and nausea or vomiting from paclitaxel.

Precautions While Using paclitaxel

It is very important that your doctor check your progress at regular visits to make sure that paclitaxel is working properly. Blood tests may be needed to check for unwanted effects.

Using paclitaxel while you are pregnant can harm your unborn baby. Use an effective form of birth control to keep from getting pregnant. If you think you have become pregnant while using the medicine, tell your doctor right away.

paclitaxel may cause serious allergic reactions, including anaphylaxis. Anaphylaxis can be life-threatening and requires immediate medical attention. Tell your doctor or nurse right away if you have a cough; dizziness; wheezing; trouble with breathing; chest or throat tightness; swelling in your face or hands; fever; chills; rash; itching or hives; skin redness; or lightheadedness or faintness while you are receiving paclitaxel.

While you are being treated with paclitaxel, and after you stop treatment with it, do not have any immunizations (vaccines) without your doctor's approval. Paclitaxel may lower your body's resistance and the vaccine may not work as well or you might get the infection the vaccine is meant to prevent. In addition, you should not be around other persons living in your household who receive live virus vaccines because there is a chance they could pass the virus on to you. Some examples of live vaccines include measles, mumps, influenza (nasal flu vaccine), poliovirus (oral form), rotavirus, and rubella. Do not get close to them and do not stay in the same room with them for very long. If you have questions about this, talk to your doctor.

Paclitaxel can temporarily lower the number of white blood cells in your blood, increasing the chance of getting an infection. It can also lower the number of platelets, which are necessary for proper blood clotting. If this occurs, there are certain precautions you can take, especially when your blood count is low, to reduce the risk of infection or bleeding:

If you can, avoid people with infections. Check with your doctor immediately if you think you are getting an infection or if you get a fever or chills, cough or hoarseness, lower back or side pain, or painful or difficult urination. Check with your doctor immediately if you notice any unusual bleeding or bruising; black, tarry stools; blood in the urine or stools; or pinpoint red spots on your skin. Be careful when using a regular toothbrush, dental floss, or toothpick. Your medical doctor, dentist, or nurse may recommend other ways to clean your teeth and gums. Check with your medical doctor before having any dental work done. Do not touch your eyes or the inside of your nose unless you have just washed your hands and have not touched anything else in the meantime. Be careful not to cut yourself when you are using sharp objects such as a safety razor or fingernail or toenail cutters. Avoid contact sports or other situations where bruising or injury could occur.

paclitaxel may cause peripheral neuropathy. Check with your doctor right away if you are having burning, numbness, tingling, or painful sensations in the arms, hands, legs, or feet while using paclitaxel.

Cancer medicines can cause diarrhea, nausea, or vomiting in most people, sometimes even after receiving medicines to prevent it. Ask your doctor or nurse about other ways to control these unwanted effects if you still have nausea or vomiting after receiving the medicine.

Do not take other medicines unless they have been discussed with your doctor. This includes prescription or nonprescription (over-the-counter [OTC]) medicines and herbal or vitamin supplements.

paclitaxel Side Effects

Along with its needed effects, a medicine may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

Check with your doctor or nurse immediately if any of the following side effects occur:

More common Black or tarry stools blurred vision burning, numbness, tingling, or painful sensations confusion cough or hoarseness with fever or chills dizziness, faintness, or lightheadedness when getting up suddenly from a lying or sitting position feeling of warmth fever or chills lower back or side pain painful or difficult urination pale skin redness of the face, neck, arms, and occasionally, upper chest shortness of breath skin rash or itching sore throat sweating troubled breathing with exertion ulcers, sores, or white spots in the mouth unsteadiness or awkwardness unusual bleeding or bruising unusual tiredness or weakness weakness in the arms, hands, legs, or feet Less common Blood in the urine or stools difficult or labored breathing pinpoint red spots on the skin shortness of breath (severe) slow heartbeat tightness in the chest wheezing Incidence not known Anxiety blue lips, fingernails, or skin difficult or troubled breathing fainting fast heartbeat irregular, fast or slow, or shallow breathing sudden shortness of breath

Some side effects may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects. Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:

More common Bleeding, blistering, burning, coldness, discoloration of the skin, feeling of pressure, hives, infection, inflammation, itching, lumps, numbness, pain, rash, redness, scarring, soreness, stinging, swelling, tenderness, tingling, ulceration, or warmth at the injection site cracked lips diarrhea difficulty with swallowing hair loss nausea or vomiting numbness, burning, or tingling in the hands or feet pain in the joints or muscles, especially in the arms or legs thinning of the hair

Other side effects not listed may also occur in some patients. If you notice any other effects, check with your healthcare professional.

Call your doctor for medical advice about side effects. You may report side effects to the FDA at 1-800-FDA-1088.

The information contained in the Thomson Reuters Micromedex products as delivered by Drugs.com is intended as an educational aid only. It is not intended as medical advice for individual conditions or treatment. It is not a substitute for a medical exam, nor does it replace the need for services provided by medical professionals. Talk to your doctor, nurse or pharmacist before taking any prescription or over the counter drugs (including any herbal medicines or supplements) or following any treatment or regimen. Only your doctor, nurse, or pharmacist can provide you with advice on what is safe and effective for you.

The use of the Thomson Reuters Healthcare products is at your sole risk. These products are provided "AS IS" and "as available" for use, without warranties of any kind, either express or implied. Thomson Reuters Healthcare and Drugs.com make no representation or warranty as to the accuracy, reliability, timeliness, usefulness or completeness of any of the information contained in the products. Additionally, THOMSON REUTERS HEALTHCARE MAKES NO REPRESENTATION OR WARRANTIES AS TO THE OPINIONS OR OTHER SERVICE OR DATA YOU MAY ACCESS, DOWNLOAD OR USE AS A RESULT OF USE OF THE THOMSON REUTERS HEALTHCARE PRODUCTS. ALL IMPLIED WARRANTIES OF MERCHANTABILITY AND FITNESS FOR A PARTICULAR PURPOSE OR USE ARE HEREBY EXCLUDED. Thomson Reuters Healthcare does not assume any responsibility or risk for your use of the Thomson Reuters Healthcare products.

More paclitaxel Intravenous resources Paclitaxel Intravenous Use in Pregnancy & Breastfeeding Paclitaxel Intravenous Drug Interactions Paclitaxel Intravenous Support Group 2 Reviews for Paclitaxel Intravenous - Add your own review/rating Compare paclitaxel Intravenous with other medications Breast Cancer Breast Cancer, Adjuvant Breast Cancer, Metastatic Kaposi's Sarcoma Non-Small Cell Lung Cancer Ovarian Cancer Wilms' Tumor

Eldoquin Forte

Generic Name: hydroquinone topical (HYE droe KWIN one) Brand Names: Aclaro, Aclaro PD, Alera, Alphaquin HP, Alustra, Claripel, Eldopaque, Eldopaque Forte, Eldoquin, Eldoquin Forte, EpiQuin Micro, Esoterica, Esoterica with Sunscreen, Glyquin, Glyquin-XM, Hydroquinone and Sunscreen, Lustra, Lustra-AF, Lustra-Ultra, Melpaque HP, Melquin HP, Melquin-3, Nuquin HP, Solaquin, Solaquin Forte

What is Eldoquin Forte (hydroquinone topical)?

Hydroquinone decreases the formation of melanin in the skin. Melanin is the pigment in skin that gives it a brown color.

Hydroquinone topical is used to lighten areas of darkened skin such as freckles, age spots, chloasma, and melasma.

Hydroquinone topical may also be used for other purposes not listed in this medication guide.

What is the most important information I should know about Eldoquin Forte (hydroquinone topical)?

Before using hydroquinone topical, tell your doctor if you are allergic to any drugs, or if you have liver or kidney disease.

Do not use hydroquinone topical on skin that is sunburned, windburned, dry, chapped, or irritated, or on an open wound. It could make these conditions worse. Wait until these conditions have healed before applying hydroquinone topical. Avoid getting this medication in your mouth or eyes. If it does get into any of these areas, rinse with water.

Avoid using skin products that can cause irritation, such as harsh soaps, shampoos, or skin cleansers, hair coloring or permanent chemicals, hair removers or waxes, or skin products with alcohol, spices, astringents, or lime. Do not use other medicated skin products unless your doctor has told you to.

Avoid exposure to sunlight or artificial UV rays (sunlamps or tanning beds). Hydroquinone topical can make your skin more sensitive to sunlight and sunburn may result. Use a sunscreen (minimum SPF 15) and wear protective clothing if you must be out in the sun. What should I discuss with my healthcare provider before using Eldoquin Forte (hydroquinone topical)? Do not use hydroquinone topical on skin that is sunburned, windburned, dry, chapped, or irritated, or on an open wound. It could make these conditions worse. Wait until these conditions have healed before applying hydroquinone topical.

Before using hydroquinone topical, tell your doctor if you are allergic to any drugs, or if you have:

liver disease; or

kidney disease.

If you have any of these conditions, you may need a dose adjustment or special tests to safely use this medication.

This medication may be harmful to an unborn baby. Tell your doctor if you are pregnant or plan to become pregnant during treatment. It is not known whether hydroquinone topical passes into breast milk or if it could harm a nursing baby. Do not use this medication without telling your doctor if you are breast-feeding a baby. How should I use Eldoquin Forte (hydroquinone topical)?

Use this medication exactly as directed on the label, or as prescribed by your doctor. Do not use it in larger amounts or for longer than recommended.

Hydroquinone topical is for external use only. Wash your hands before and after applying this medication, unless you are treating a skin area on your hand.

Apply the medication to clean, dry skin. Apply just enough medication to cover the affected area. Avoid applying to the unaffected surrounding skin. Rub in the medication gently and completely.

Avoid getting this medication on your lips or inside your nose or mouth. Hydroquinone may cause numbness of these areas. If the medication does get on any of these areas, rinse with water.

It is important to use hydroquinone topical regularly to get the most benefit.

Store hydroquinone topical at room temperature away from moisture and heat. What happens if I miss a dose?

Use the missed dose as soon as you remember. If it is almost time for your next dose, wait until then to use the medicine and skip the missed dose. Do not use extra medicine to make up the missed dose.

What happens if I overdose? Seek emergency medical attention if you think you have used too much of this medicine.

An overdose of topically applied hydroquinone is not likely to cause life-threatening symptoms.

What should I avoid while using Eldoquin Forte (hydroquinone topical)? Avoid getting this medication in your mouth or eyes. If it does get into any of these areas, rinse with water. Do not use hydroquinone topical on sunburned, windburned, dry, chapped, irritated, or broken skin.

Your skin may be more sensitive to weather extremes such as cold and wind. Protect your skin with clothing and use a moisturizing cream or lotion as needed.

Avoid using skin products that can cause irritation, such as harsh soaps, shampoos, or skin cleansers, hair coloring or permanent chemicals, hair removers or waxes, or skin products with alcohol, spices, astringents, or lime. Do not use other medicated skin products unless your doctor has told you to.

Using hydroquinone topical together with benzoyl peroxide, hydrogen peroxide, or other peroxide products may cause a temporary staining of your skin. This staining can usually be removed with soap and water. Avoid exposure to sunlight or artificial UV rays (sunlamps or tanning beds). Hydroquinone topical can make your skin more sensitive to sunlight and sunburn may result. Use a sunscreen (minimum SPF 15) and wear protective clothing if you must be out in the sun. Eldoquin Forte (hydroquinone topical) side effects Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficulty breathing; swelling of your face, lips, tongue, or throat. Stop using hydroquinone topical and call your doctor if you have severe burning, stinging, or other irritation of your skin after apply the medication.

Less serious side effects may include mild burning, stinging, itching, redness, or irritation of treated skin.

This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

What other drugs will affect Eldoquin Forte (hydroquinone topical)?

It is not likely that other drugs you take orally or inject will have an effect on topically applied hydroquinone. But many drugs can interact with each other. Tell your doctor about all your prescription and over-the-counter medications, vitamins, minerals, herbal products, and drugs prescribed by other doctors. Do not start a new medication without telling your doctor.

More Eldoquin Forte resources Eldoquin Forte Side Effects (in more detail) Eldoquin Forte Use in Pregnancy & Breastfeeding Eldoquin Forte Support Group 0 Reviews for Eldoquin Forte - Add your own review/rating Alustra MedFacts Consumer Leaflet (Wolters Kluwer) Epiquin Micro Prescribing Information (FDA) Esoterica Cream MedFacts Consumer Leaflet (Wolters Kluwer) Solaquin Forte Cream MedFacts Consumer Leaflet (Wolters Kluwer) Compare Eldoquin Forte with other medications Dermatological Disorders Where can I get more information? Your pharmacist can provide more information about hydroquinone topical.

See also: Eldoquin Forte side effects (in more detail)

Lodine
Generic Name: etodolac Dosage Form: Capsules and Tablets

Rx only

Cardiovascular Risk NSAIDs may cause an increased risk of serious cardiovascular thrombotic events, myocardial infarction (MI), and stroke, which can be fatal. This risk may increase with duration of use. Patients with cardiovascular disease or risk factors for cardiovascular disease may be at greater risk. (See WARNINGS and CLINICAL TRIALS.) Lodine is contraindicated for the treatment of peri-operative pain in the setting of coronary artery bypass graft (CABG) surgery. (See WARNINGS.) Gastrointestinal Risk NSAIDs cause an increased risk of serious gastrointestinal adverse events including bleeding, ulceration, and perforation of the stomach or intestines, which can be fatal. These events can occur at any time during use and without warning symptoms. Elderly patients are at greater risk for serious gastrointestinal (GI) events. (See WARNINGS.) DESCRIPTION

Lodine® (etodolac) is a member of the pyranocarboxylic acid group of nonsteroidal anti-inflammatory drugs (NSAIDs). Each tablet and capsule contains etodolac for oral administration. Etodolac is a racemic mixture of [+]S and [-]R-enantiomers. Etodolac is a white crystalline compound, insoluble in water but soluble in alcohols, chloroform, dimethyl sulfoxide, and aqueous polyethylene glycol.

The chemical name is (±) 1,8-diethyl-1,3,4,9-tetrahydropyrano-[3,4-b]indole-1-acetic acid. The molecular weight of the base is 287.37. It has a pKa of 4.65 and an n-octanol:water partition coefficient of 11.4 at pH 7.4. The molecular formula for etodolac is C17H21NO3, and it has the following structural formula:

The inactive ingredients in Lodine include:

—in capsules: cellulose, gelatin, iron oxides, lactose, magnesium stearate,povidone, sodium lauryl sulfate, sodium starch glycolate, and titanium dioxide.

—in tablets: cellulose, hypromellose, lactose, magnesium stearate, polyethylene glycol, polysorbate 80, povidone, sodium starch glycolate, and titanium dioxide. The 400 mg tablets contain D&C Yellow #10, FD&C Blue #2, and FD&C Yellow #6 as color additives. The 500 mg tablets contain FD&C Blue #2 only.

CLINICAL PHARMACOLOGY Pharmacodynamics

Lodine is a nonsteroidal anti-inflammatory drug (NSAID) that exhibits anti-inflammatory, analgesic, and antipyretic activities in animal models. The mechanism of action of Lodine, like that of other NSAIDs, is not completely understood, but may be related to prostaglandin synthetase inhibition.

Lodine is a racemic mixture of [-]R- and [+]S-etodolac. As with other NSAIDs, it has been demonstrated in animals that the [+]S-form is biologically active. Both enantiomers are stable and there is no [-]R to [+]S conversion in vivo.

Pharmacokinetics Absorption

The systemic bioavailability of etodolac from Lodine is 100% as compared to solution and at least 80% as determined from mass balance studies. Etodolac is well absorbed and had a relative bioavailability of 100% when 200 mg capsules were compared with a solution of etodolac. Based on mass balance studies, the systemic availability of etodolac from either the tablet or capsule formulation is at least 80%. Etodolac does not undergo significant first-pass metabolism following oral administration. Mean (± 1 SD) peak plasma concentrations (Cmax) range from approximately 14 ± 4 to 37 ± 9 ?g/mL after 200 to 600 mg single doses and are reached in 80 ± 30 minutes (see Table 1 for summary of pharmacokinetic parameters). The dose-proportionality based on the area under the plasma concentration-time curve (AUC) is linear following doses up to 600 mg every 12 hours. Peak concentrations are dose proportional for both total and free etodolac following doses up to 400 mg every 12 hours, but following a 600 mg dose, the peak is about 20% higher than predicted on the basis of lower doses. The extent of absorption of etodolac is not affected when Lodine is administered after a meal. Food intake, however, reduces the peak concentration reached by approximately one-half and increases the time to peak concentration by 1.4 to 3.8 hours.

Table 1. Mean (CV%)† Pharmacokinetic Parameters of Lodine in Normal Healthy Adults and Various Special Populations

†% Coefficient of variation

*Age Range (years)

NA = not available

Moxifloxacin Hydrochloride eent

Class: AntibacterialsVA Class: AM900Chemical Name: (4aS - cis) - 1 - Cyclopropyl - 6 - fluoro - 1,4 - dihydro - 8 - methoxy - 7 - (octahydro - 6H - pyrrolol[3,4 - b]pyridin - 6 - yl) - 4 - oxo - 3 - quinolinecarboxylic acid monohydrochloride

Bacterial Endocarditis Prevention (Bacterial Endocarditis Prophylaxis) Medications
Drugs associated with Bacterial Endocarditis Prevention

The following drugs and medications are in some way related to, or used in the treatment of Bacterial Endocarditis Prevention. This service should be used as a supplement to, and NOT a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

Learn more about Bacterial Endocarditis Prevention (Bacterial Endocarditis Prophylaxis)

Medical Encyclopedia:

Endocarditis Infectious endocarditis Drug List: Amoxil Ancef Azithromycin-3-Day-Dose-Pack Biaxin Biaxin-Xl-Extended-Release-Tablets Bio-Cef Cleocin Cleocin-Hcl Cleocin-Pediatric-Suspension Cleocin-Phosphate-Iv Dispermox Duricef E-E-S-Granules-Suspension E-E-S-200 E-E-S-400 E-E-S-400-Filmtab Ery-Tab Eryc-Delayed-Release-Particles-Capsules Eryped-Drops Erythrocin Erythromycin-Lactobionate-I-V Erythrocin-Stearate-Filmtab Garamycin-Solution Ilosone Keflex Kefzol Lyphocin Panixine Pce Principen Rocephin Trimox Vancocin Vancocin-Hcl Vancocin-Hcl-Pulvules Zithromax Zmax-Extended-Release-Oral-Suspension

Hypertensive Heart Disease Medications

Definition of Hypertensive Heart Disease: Hypertensive heart disease is a late complication of hypertension (high blood pressure) that affects the heart.

Topics under Hypertensive Heart Disease Hypertensive Congestive Heart Failure (0 drugs) Learn more about Hypertensive Heart Disease

Medical Encyclopedia:

Anesthesia Hypertensive heart disease Drug List:

Mintec or 0.2ml gastro-resistant capsules
1. Name Of The Medicinal Product

Mintec or 0.2ml gastro-resistant capsules

2. Qualitative And Quantitative Composition

Each capsule contains 0.2ml peppermint oil.

For a full list of excipients, see section 6.1.

3. Pharmaceutical Form

Gastro-resistant capsules, soft (for oral use).

Size no. 4, one half of capsule is green, the other half is ivory.

4. Clinical Particulars 4.1 Therapeutic Indications

Symptomatic relief of irritable bowel or spastic colon syndrome.

4.2 Posology And Method Of Administration

Adults: one capsule orally three times a day, preferably before meals with a small quantity of water, but not immediately after food. The capsules must not be broken or chewed.

When symptoms are more severe, the dose may be increased to two capsules three times a day.

Mintec should be taken until symptoms resolve, but may be continued for up to 2 to 3 months.

Elderly: Dose as for adults.

Paediatric patients: Mintec is not recommended for children.

4.3 Contraindications

Hypersensitivity to peppermint oil, salicylates or to any other excipients of Mintec.

4.4 Special Warnings And Precautions For Use

If this is the first occurrence of these symptoms, a doctor should be consulted before self medication begins, to confirm the appropriateness of the treatment.

Before beginning self medication, a doctor should be consulted if:

The patient is over 40 years old and it is some time since the last attack of irritable bowel or spastic colon syndrome, or the symptoms have changed; blood has been passed from the bowel; the patient has experienced nausea or vomiting, loss of appetite or loss of weight, paleness and tiredness, severe constipation, fever, abnormal vaginal bleeding or discharge, difficulty or pain in passing urine.

If the patient has recently travelled abroad, or is pregnant or possibly pregnant, they should consult their doctor prior to self medication.

If there are new symptoms or worsening of the condition or failure to improve over two weeks of treatment, the patient should consult their doctor.

In patients with pre-existing heartburn, symptoms may be exacerbated.

4.5 Interaction With Other Medicinal Products And Other Forms Of Interaction

None known.

4.6 Pregnancy And Lactation

The usual precautions concerning the administration of any drug during pregnancy should be observed.

4.7 Effects On Ability To Drive And Use Machines

Mintec has no known influence on the ability to drive and use machines.

4.8 Undesirable Effects

Heartburn, and rarely allergic reactions including erythematous skin rash, bradycardia, muscle tremor and ataxia, which may also occur in association with alcohol.

4.9 Overdose

Treatment consists of gastric lavage, together with symptomatic and supportive measures.

5. Pharmacological Properties 5.1 Pharmacodynamic Properties

Pharmacotherapeutic group: Drugs for function bowel disorders.

ATC Code: A03A Drugs for functional bowel disorders; A02D (Antiflatulents).

Mintec (peppermint oil) is an aromatic carminative which acts locally to relax gastro intestinal smooth muscle and relieve gastro-intestinal flatulence and colic. The enteric coating of the capsules is designed to delay release of the peppermint oil beyond the stomach and upper small bowel.

5.2 Pharmacokinetic Properties

An open cross-over study was conducted in eight healthy volunteers, to compare the excretion pattern of menthol (the major constituent of peppermint,oil) from peppermint oil contained in gastro-resistant soft gelatin capsules (Mintec), and similar, uncoated capsules. In each leg of the study, each volunteer received 0.4 ml of peppermint oil as two capsules of one of the preparations. The excretion of the oil in the urine (as the glucuronide) was followed over a 24 hour period.

Mintec capsules significantly delayed the rate of excretion of menthol compared with the non-coated capsules.

The maximum amounts of menthol were excreted within 0 to 2 hours following administration of uncoated capsules and between 2 to 4 hours following Mintec administration. There were no significant differences between treatments in terms of the maximum or total amounts of menthol excreted over the 24 hour post-dose period.

5.3 Preclinical Safety Data

No additional data available.

6. Pharmaceutical Particulars 6.1 List Of Excipients

Capsule shell:

Gelatin

Glycerol

Titanium dioxide (E171)

Chlorophyll KK (E141)

Enteric coat:

Hydroxypropylmethyl cellulose phthalate

Dibutyl phthalate

6.2 Incompatibilities

Not applicable.

6.3 Shelf Life

30 months.

6.4 Special Precautions For Storage

Do not store above 25?C.

In order to protect from light, store in the original package.

6.5 Nature And Contents Of Container

Aluminium/PVC/PVDC blister strips in packs of 2, 3 (sample), 4, 6, 12, 24, 25, 84 and 100.

Not all pack sizes may be marketed.

6.6 Special Precautions For Disposal And Other Handling

None.

Administrative Data 7. Marketing Authorisation Holder

Almirall S.A

General Mitre 151

08022 Barcelona

Spain

8. Marketing Authorisation Number(S)

PL 16973/0020

9. Date Of First Authorisation/Renewal Of The Authorisation

17/06/2008

10. Date Of Revision Of The Text

3 September 2010

Cuvposa Solution
Pronunciation: GLYE-koe-PIR-oh-lateGeneric Name: GlycopyrrolateBrand Name: Cuvposa

2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 ... 78 Next →